Xtant Medical Reports Third Quarter 2024 Financial Results
Third Quarter Revenue Growth of 12%
Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 Million
Representing Growth of 27% to 31%
BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2024.
Third Quarter 2024 Financial Highlights
-
Revenue of $27.9 million, up 12%, compared to the prior year quarter; year to date revenue of $85.8 million, up 36% compared to prior year period
-
Gross margin of 58.4% compared to 61.3% for the prior year quarter
-
Net loss of $5.0 million compared to net income of $9.2 million in the prior year quarter which included a $11.0 million bargain purchase gain related to the acquisition of Surgalign Holdings
-
Adjusted EBITDA of $(196,000) compared to $440,000 in the prior year quarter
Recent Business Highlights
-
Launched OsteoVive+, a moldable, viable bone matrix for use in a variety of grafting procedures
-
Launched Cortera Posterior Fixation System, a comprehensive solution designed to streamline thoracolumbar fixation surgeries
-
Signed a license agreement for Q-Codes and corresponding SimpliMax Dual Layer Amniotic Membrane, which provides for a minimum of $5.25 million in licensing and royalty fees
-
Completed $5.0 million private placement on August 9, 2024
Sean Browne, President and CEO of Xtant Medical, stated, “During the third quarter, we expanded our market opportunities with the launch of two new products, OsteoVive+ (stem cells) and Cortera Posterior Fixation System. Importantly, OsetoVive+ is produced internally to our high standards, giving us greater control over the supply chain and enabling a higher margin contribution on incremental sales, which we expect to accelerate in the fourth quarter.”
Browne continued, “2024 is shaping up largely as we planned with revenue growth of 36% year-to-date. We are therefore reaffirming our full year revenue guidance of $116 million to $120 million. The growth we expect in the fourth quarter will be driven by the strength of our products, continued strong operational execution and importantly, it will be entirely organic. The market opportunities in biologics are expansive, and we are striving to build a resilient and scalable business, which we believe will drive long-term growth and increase profitability for our stockholders.”
Third Quarter 2024 Financial Results
Total revenue for the three months ended September 30, 2024 was $27.9 million, an increase of 12%, compared to $25.0 million in the prior year quarter. The increase is primarily due to the contribution of additional sales resulting from the acquisition of the Surgalign Holdings’ hardware and biologics business, which was partially offset by reduced surgical procedures using our products.
Gross margin for the third quarter of 2024 was 58.4%, compared to 61.3% for the prior year quarter. The decrease is primarily due to reduced production throughput, partially offset by additional scale.
Operating expenses for the third quarter of 2024 totaled $20.1 million, an increase of 7.3% compared to $18.7 million for the third quarter of 2023. The increase was primarily due to additional commission expense resulting from revenue growth, additional compensation expense related to additional headcount and additional stock-based compensation.
Net loss for the third quarter of 2024 was $5.0 million, or $(0.04) per share, compared to net income of $9.2 million, or $0.07 per share in the prior year quarter. Net income for the third quarter of 2023 includes a bargain purchase gain of $11.0 million related to the acquisition of Surgalign Holdings’ hardware and biologics business in August 2023.
Non-GAAP Adjusted EBITDA for the third quarter of 2024 was a loss of $196,000, compared to non-GAAP Adjusted EBITDA of $440,000 for the prior-year period. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income tax/benefit, and as further adjusted to add back in or exclude, as applicable, separation related expenses, legal settlements, non-cash compensation, acquisition-related expenses, acquisition-related fair value adjustments, gain on bargain purchase and foreign currency exchange gains/losses. A calculation and reconciliation of Adjusted EBITDA to net loss can be found in the attached financial tables.
As of September 30, 2024, the Company had $6.6 million of cash and cash equivalents compared to $5.7 million as of December 31, 2023.
2024 Financial Guidance
Xtant Medical reaffirmed its full year 2024 revenue guidance of $116 million to $120 million. Revenue guidance for 2024 represents annual growth of 27% to 31%.
Conference Call
Xtant Medical will host a webcast and conference call to discuss third quarter 2024 financial results at 4:30 pm ET on Tuesday, November 12, 2024.
To access the webcast, visit https://www.webcaster4.com/Webcast/Page/3039/51623.
To access the conference call, dial 888-999-3182 within the U.S. or 848-280-6330 outside the U.S. Passcode: Xtant Medical Holdings.
A replay of the call will be available on the Investor section of the Company’s website at www.xtantmedical.com.
About Xtant Medical Holdings, Inc.
Xtant Medical’s mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Non-GAAP Financial Measures
To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “intends,” ‘‘expects,” ‘‘anticipates,” ‘‘plans,” ‘‘believes,” ‘‘estimates,” “continue,” “future,” ‘‘will,” “potential,” “going forward,” “guidance,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s financial guidance for 2024, expectations for the acceleration of incremental sales in the fourth quarter, the Company’s ability to build a resilient and scalable business, the Company’s anticipated long-term growth and increased profitability for stockholders. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results and financial performance; its ability to increase or maintain revenue; the Company’s ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with its acquisitions and the integration of those businesses; anticipated shortages of stem cells which will adversely affect future revenues; the ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory; the ability to remain competitive; the ability to innovate, develop and introduce new products and the success of those products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company’s dependence on key independent agents for a significant portion of its revenue; the effect of labor and hospital staffing shortages on the Company’s business, operating results and financial condition, especially when they affect key markets; the effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company’s financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to license certain of the Company’s intellectual property on commercially reasonable terms and to maintain any such licenses; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; risks associated with the Company’s clinical trials; international risks; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to maintain sufficient liquidity to fund its operations and obtain financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on April 1, 2024 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 anticipated to be filed with the SEC. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.
Investor Relations Contact:
Brett Maas
Managing Partner, Hayden IR
brett@haydenir.com
(646) 536-7331
XTANT MEDICAL HOLDINGS, INC.
Condensed Consolidated Balance Sheets
(In thousands, except number of shares and par value)
|
September 30, 2024 |
December 31, 2023 |
|||||||
|
ASSETS
|
||||||||
|
Current Assets:
|
||||||||
|
Cash and cash equivalents
|
$ |
6,596 |
$ |
5,715 |
||||
|
Restricted cash
|
490 |
208 |
||||||
|
Trade accounts receivable, net of allowance for
credit losses and doubtful accounts of $1,038 and $920, respectively |
20,545 |
20,731 |
||||||
|
Inventories
|
41,886 |
36,885 |
||||||
|
Prepaid and other current assets
|
1,893 |
1,330 |
||||||
|
Total current assets
|
71,410 |
64,869 |
||||||
|
|
||||||||
|
Property and equipment, net
|
10,284 |
8,692 |
||||||
|
Right-of -use asset, net
|
995 |
1,523 |
||||||
|
Goodwill
|
7,302 |
7,302 |
||||||
|
Intangible assets, net
|
8,788 |
10,085 |
||||||
|
Other assets
|
103 |
141 |
||||||
|
Total Assets
|
$ |
98,882 |
$ |
92,612 |
||||
|
|
||||||||
|
LIABILITIES & STOCKHOLDERS’ EQUITY
|
||||||||
|
Current Liabilities:
|
||||||||
|
Accounts payable
|
$ |
8,298 |
$ |
7,054 |
||||
|
Accrued liabilities
|
8,871 |
10,419 |
||||||
|
Current portion of lease liability
|
795 |
830 |
||||||
|
Current portion of finance lease obligations
|
68 |
65 |
||||||
|
Line of credit
|
12,887 |
4,622 |
||||||
|
Current portion of long-term debt
|
2,750 |
– |
||||||
|
Total current liabilities
|
33,669 |
22,990 |
||||||
|
Long-term Liabilities:
|
||||||||
|
Lease liability, less current portion
|
247 |
759 |
||||||
|
Finance lease obligations, less current portion
|
65 |
116 |
||||||
|
Long-term debt, plus premium and less issuance costs
|
19,138 |
17,167 |
||||||
|
Other liabilities
|
38 |
231 |
||||||
|
Total Liabilities
|
53,157 |
41,263 |
||||||
|
|
||||||||
|
Commitments and Contingencies
|
– |
– |
||||||
|
Stockholders’ Equity
|
||||||||
|
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding
|
– |
– |
||||||
|
Common stock, $0.000001 par value; 300,000,000 shares authorized; 138,680,874 shares issued and outstanding as of September 30, 2024 and 130,180,031 shares issued and outstanding as of December 31, 2023
|
– |
– |
||||||
|
Additional paid-in capital
|
301,966 |
294,330 |
||||||
|
Accumulated other comprehensive (loss) income
|
54 |
29 |
||||||
|
Accumulated deficit
|
(256,295 |
) |
(243,010 |
) |
||||
|
Total Stockholders’ Equity
|
45,725 |
51,349 |
||||||
|
|
||||||||
|
Total Liabilities & Stockholders’ Equity
|
$ |
98,882 |
$ |
92,612 |
||||
XTANT MEDICAL HOLDINGS, INC.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except number of shares and per share amounts)
|
Three Months Ended |
Nine Months Ended |
|||||||||||||||
|
2024 |
2023 |
2024 |
2023 |
|||||||||||||
|
Revenue
|
$ |
27,937 |
$ |
25,019 |
$ |
85,754 |
$ |
63,195 |
||||||||
|
Cost of sales
|
11,630 |
9,685 |
33,562 |
24,865 |
||||||||||||
|
Gross Profit
|
16,307 |
15,334 |
52,192 |
38,330 |
||||||||||||
|
|
||||||||||||||||
|
Gross Profit %
|
58.4 |
% |
61.3 |
% |
60.9 |
% |
60.7 |
% |
||||||||
|
|
||||||||||||||||
|
Operating Expenses
|
||||||||||||||||
|
General and administrative
|
7,493 |
7,144 |
22,991 |
16,983 |
||||||||||||
|
Sales and marketing
|
11,890 |
11,085 |
37,530 |
26,855 |
||||||||||||
|
Research and development
|
701 |
490 |
1,863 |
844 |
||||||||||||
|
Total Operating Expenses
|
20,084 |
18,719 |
62,384 |
44,682 |
||||||||||||
|
|
||||||||||||||||
|
Loss from Operations
|
(3,777 |
) |
(3,385 |
) |
(10,192 |
) |
(6,352 |
) |
||||||||
|
|
||||||||||||||||
|
Other (Expense) Income
|
||||||||||||||||
|
Interest expense
|
(1,199 |
) |
(760 |
) |
(3,026 |
) |
(2,120 |
) |
||||||||
|
Interest income
|
– |
48 |
– |
133 |
||||||||||||
|
Foreign currency exchange gain
|
27 |
– |
106 |
– |
||||||||||||
|
Other expense
|
(13 |
) |
– |
(6 |
) |
– |
||||||||||
|
Bargain purchase gain
|
– |
11,028 |
– |
11,028 |
||||||||||||
|
Total Other (Expense) Income
|
(1,185 |
) |
10,316 |
(2,926 |
) |
9,041 |
||||||||||
|
Net (Loss) Income from Operations Before Provision for Income Taxes
|
(4,962 |
) |
6,931 |
(13,118 |
) |
2,689 |
||||||||||
|
|
||||||||||||||||
|
Provision for Income Taxes
|
||||||||||||||||
|
Current and Deferred
|
(62 |
) |
2,300 |
(166 |
) |
2,274 |
||||||||||
|
Net (Loss) Income
|
$ |
(5,024 |
) |
$ |
9,231 |
$ |
(13,284 |
) |
$ |
4,963 |
||||||
|
|
||||||||||||||||
|
Net (Loss) Income Per Share:
|
||||||||||||||||
|
Basic
|
$ |
(0.04 |
) |
$ |
0.07 |
$ |
(0.10 |
) |
$ |
0.04 |
||||||
|
Dilutive
|
$ |
(0.04 |
) |
$ |
0.07 |
$ |
(0.10 |
) |
$ |
0.04 |
||||||
|
|
||||||||||||||||
|
Shares used in the computation:
|
||||||||||||||||
|
Basic
|
135,100,233 |
128,140,238 |
131,881,302 |
115,380,792 |
||||||||||||
|
Dilutive
|
135,100,233 |
135,663,274 |
131,881,302 |
123,832,401 |
||||||||||||
XTANT MEDICAL HOLDINGS, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)
|
Nine Months Ended |
||||||||
|
2024 |
2023 |
|||||||
|
Operating activities:
|
||||||||
|
Net (loss) income
|
$ |
(13,284 |
) |
$ |
4,963 |
|||
|
Adjustments to reconcile net (loss) income to net cash used in operating activities:
|
||||||||
|
Depreciation and amortization
|
3,076 |
2,157 |
||||||
|
Gain on disposal of fixed assets
|
(182 |
) |
(104 |
) |
||||
|
Non-cash interest
|
369 |
266 |
||||||
|
Non-cash rent
|
(18 |
) |
5 |
|||||
|
Stock-based compensation
|
3,277 |
1,801 |
||||||
|
Provision for expected credit losses
|
330 |
316 |
||||||
|
Provision for excess and obsolete inventory
|
695 |
398 |
||||||
|
Release of valuation allowance
|
– |
(2,394 |
) |
|||||
|
Gain on bargain purchase
|
– |
(11,028 |
) |
|||||
|
Other
|
17 |
– |
||||||
|
|
||||||||
|
Changes in operating assets and liabilities, net of the effects of the acquisition:
|
||||||||
|
Accounts receivable
|
(128 |
) |
(7,047 |
) |
||||
|
Inventories
|
(5,657 |
) |
(1,669 |
) |
||||
|
Prepaid and other assets
|
(503 |
) |
69 |
|||||
|
Accounts payable
|
1,290 |
1,298 |
||||||
|
Accrued liabilities
|
(1,843 |
) |
2,369 |
|||||
|
Net cash used in by operating activities
|
(12,561 |
) |
(8,600 |
) |
||||
|
Investing activities:
|
||||||||
|
Purchases of property and equipment
|
(3,441 |
) |
(1,093 |
) |
||||
|
Proceeds from sale of fixed assets
|
278 |
70 |
||||||
|
Acquisition of Surgalign SPV, Inc.
|
– |
(17,000 |
) |
|||||
|
Acquisition of Surgalign Holding, Inc.’s hardware and biologics business, net of cash acquired
|
– |
(4,448 |
) |
|||||
|
Net cash used in investing activities
|
(3,163 |
) |
(22,471 |
) |
||||
|
Financing activities:
|
||||||||
|
Payments on financing leases
|
(49 |
) |
(46 |
) |
||||
|
Borrowings on line of credit
|
86,315 |
55,345 |
||||||
|
Repayments of line of credit
|
(78,050 |
) |
(54,724 |
) |
||||
|
Proceeds from private placement, net of cash issuance costs
|
4,456 |
14,011 |
||||||
|
Proceeds from issuance of long-term debt, net of issuance costs
|
5,000 |
4,899 |
||||||
|
Payments on long term debt
|
(648 |
) |
– |
|||||
|
Proceeds from exercise of stock based compensation
|
13 |
– |
||||||
|
Payment of taxes from withholding of common stock on vesting of restricted stock units
|
(110 |
) |
(119 |
) |
||||
|
Net cash provided by financing activities
|
16,927 |
19,366 |
||||||
|
|
||||||||
|
Effect of exchange rate changes on cash and cash equivalents and restricted cash
|
(40 |
) |
(53 |
) |
||||
|
|
||||||||
|
Net change in cash and cash equivalents and restricted cash
|
1,163 |
(11,758 |
) |
|||||
|
Cash and cash equivalents and restricted cash at beginning of period
|
5,923 |
20,507 |
||||||
|
Cash and cash equivalents and restricted cash at end of period
|
$ |
7,086 |
$ |
8,749 |
||||
|
|
||||||||
|
Reconciliation of cash and restricted cash reported in the condensed consolidated balance sheets
|
||||||||
|
Cash and cash equivalents
|
$ |
6,596 |
$ |
8,664 |
||||
|
Restricted cash
|
490 |
85 |
||||||
|
Total cash and restricted cash reported in the condensed consolidated balance sheets
|
$ |
7,086 |
$ |
8,749 |
||||
XTANT MEDICAL HOLDINGS, INC.
Calculation of Non-GAAP Consolidated EBITDA and Adjusted EBITDA
(Unaudited, in thousands)
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
|
2024 |
2023 |
2024 |
2023 |
|||||||||||||
|
Net (Loss) Income
|
$ |
(5,024 |
) |
$ |
9,231 |
$ |
(13,284 |
) |
$ |
4,963 |
||||||
|
|
||||||||||||||||
|
Depreciation and amortization
|
1,073 |
883 |
3,076 |
2,157 |
||||||||||||
|
Interest expense
|
1,199 |
712 |
3,026 |
1,987 |
||||||||||||
|
Tax expense (benefit)
|
62 |
(2,300 |
) |
166 |
(2,274 |
) |
||||||||||
|
Non-GAAP EBITDA
|
(2,690 |
) |
8,526 |
(7,016 |
) |
6,833 |
||||||||||
|
|
||||||||||||||||
|
Non-GAAP EBITDA/Total revenue
|
-9.6 |
% |
34.1 |
% |
-8.2 |
% |
10.8 |
% |
||||||||
|
|
||||||||||||||||
|
NON-GAAP ADJUSTED EBITDA CALCULATION
|
||||||||||||||||
|
Separation related expenses
|
464 |
– |
490 |
(15 |
) |
|||||||||||
|
Legal settlements
|
– |
140 |
– |
140 |
||||||||||||
|
Non-cash compensation
|
1,139 |
745 |
3,277 |
1,801 |
||||||||||||
|
Acquisition-related expenses
|
– |
1,023 |
338 |
1,326 |
||||||||||||
|
Acquisition-related fair value adjustments
|
918 |
1,026 |
3,448 |
1,188 |
||||||||||||
|
Gain on bargain purchase
|
– |
(11,028 |
) |
– |
(11,028 |
) |
||||||||||
|
Unrealized foreign currency translation (gain) loss
|
(27 |
) |
8 |
(106 |
) |
8 |
||||||||||
|
Non-GAAP Adjusted EBITDA
|
$ |
(196 |
) |
$ |
440 |
$ |
431 |
$ |
253 |
|||||||
|
|
||||||||||||||||
SOURCE: Xtant Medical Holdings, Inc.
View the original press release on accesswire.com
